PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial
Combination immunotherapy of GR-MD-02 and KEYTRUDA for all cohorts reported shows an Objective Response Rate of 50% (seven of fourteen patients). The published response rate of KEYTRUDA alone is 33% in melanoma Providence Portland principal investigator, Dr.
View HTML
Toggle Summary Galectin Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference
NORCROSS, Ga. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the H.C.
View HTML
Toggle Summary Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for its second fiscal quarter, which ended June 30, 2018 , and provided a business update.
View HTML
Toggle Summary Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
NORCROSS, Ga. , June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631  titled
View HTML
Toggle Summary Company Profile for Galectin Therapeutics Inc.
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces New CEO
NORCROSS, Ga. , June 12, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin , Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive
View HTML
Toggle Summary Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board
NORCROSS, Ga. , June 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the directors elected Richard E. Uihlein as Chairman of the Board of Directors. Additionally, Kevin D.
View HTML
Toggle Summary Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting
NORCROSS, Ga. , May 14, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today it is proceeding with plans for a Phase 3 clinical trial program with its galectin-3 inhibitor GR-MD-02 in NASH cirrhosis,
View HTML
Toggle Summary Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , May 11, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the three months ended March 31, 2018 , and provided a business update.
View HTML
Toggle Summary Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
NORCROSS, Ga. , April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will participate in
View HTML